Talquetamab - Genmab/Janssen Research & Development
Alternative Names: GPRC5D/CD3-duobody-antibody-JNJ-64407564; JNJ 64407564; JNJ-7564; TALVEYLatest Information Update: 02 Sep 2024
At a glance
- Originator Genmab; Janssen Research & Development
- Developer Janssen Research & Development
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Multiple myeloma
- Phase II Smoldering multiple myeloma
Most Recent Events
- 23 Aug 2024 Phase-II clinical trials in Multiple myeloma (Second-line therapy or greater) in United Kingdom (Northern Ireland), United Kingdom, Netherlands, Brazil (SC) (ISRCTN72589181)
- 19 Aug 2024 Janssen Research & Development plans a phase II MonumenTAL-8 trial for Multiple Myeloma (Combination therapy, Second-line therapy or greater) in September 2024 (SC) (NCT06550895)
- 18 Jul 2024 Janssen Research & Development plans a phase II trial for Multiple meyloma (Second-line therapy or greater) (SC) in Brazil, England, Netherlands, South Korea, Spain, United Kingdom, United Kingdom (Northern Ireland), USA in August 2024 (NCT06500884)